HHS, FDA Announce Multiple Initiatives on Food Safety, Quality and Compliance Fronts

March 24, 2025

Reading Time : 2 min

In the past week, the U.S. Food and Drug Administration (FDA), in collaboration with the Department of Health and Human Services (HHS) announced three new initiatives related to food safety and food supply chain transparency. Outlined below, these new initiatives align with HHS Secretary Robert F. Kennedy Jr.’s recent announcements to focus on bolstering food safety, including the recent directive to the FDA to explore the revision of the longstanding Generally Recognized as Safe (GRAS) rule.

Operation Stork Speed

On March 18, 2025, HHS and FDA announced “Operation Stork Speed,” aimed at enhancing the safety, nutritional quality and availability of infant formula. Through this initiative, FDA plans to increase testing for heavy metals and other contaminants in infant formula. The agency is also calling on industry to “develop new infant formulas and clarify opportunities to help inform consumers about formula ingredients.” The agency states that it will use “both longstanding and newly granted” authorities to carry out its stated goals, including:

  • Issuing a Request for Information (RFI) to start a comprehensive update and review of infant formula nutrients;
  • Increasing testing for heavy metals and other contaminants in infant formula and other children foods;
  • Extending the personal importation policy; and
  • Working with both industry and consumer stakeholders to increase transparency and collaborating with the National Institutes of Health (NIH) and other scientific bodies to address scientific research gaps related to health outcomes associated with formula feeding.

Chemical Contaminants Transparency Tool for Foods

On March 20, 2025, the agency unveiled the Chemical Contaminants Transparency Tool (CCT Tool), a searchable online database that consolidates information on contaminant levels in human foods. The database lists the contaminant name, commodity, contaminant level type, level value and reference. To date, FDA has published a variety of contaminant levels for poisonous or deleterious substances in food in various guidance documents and regulations for industry. With the CCT Tool, the agency aims to consolidate this information for ease of reference. Certain contaminant levels such as allowable levels listed in the quality standard for bottled water and marine biotoxin safety levels are not included in the tool.

Extension of Compliance Date for Food Traceability Rule

Also, on March 20, 2025, the agency announced its intention to extend the compliance date for its 2022 final rule on Requirements for Additional Traceability Records for Certain Foods (Food Traceability Final Rule) by 30 months. Implementing Section 204(d) of the Food Safety Modernization Act (FSMA), the Food Traceability Rule mandates enhanced recordkeeping requirements for certain high-risk foods to improve the agency’s ability to respond to foodborne illness outbreaks and contamination events. Citing concerns among covered entities about meeting the initial compliance deadline of January 2026, FDA plans to extend the compliance date using notice and comment rulemaking at a later date. FDA intends to engage with stakeholders and assist industry with implementation.

Industry participants should expect to see further policy updates and closely monitor forthcoming guidance.

 

Share This Insight

Previous Entries

Eye on FDA

May 12, 2025

On May 9, 2025, the U.S. Food and Drug Administration (FDA) granted three color additive petitions, approving two new colorings and expanding one existing approval. These approvals come after the agency’s announcement last month to phase out all petroleum-based synthetic dyes in food by the end of 2026 and transition to natural alternatives (see our post here). Under section 721 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), color additives (unless exempt from batch certification) are subject to FDA approval to determine their safety for use in food. The agency evaluates the safety of color additives based on multiple factors including projected human dietary exposure to the additive, toxicological data, and other relevant information. Once FDA approves a color additive petition, any manufacturer can use the additive in foods for the approved intended uses.

...

Read More

Eye on FDA

May 8, 2025

In the last two weeks, the Department of Health and Human Services (HHS) has filled key artificial intelligence (AI) positions at HHS and the U.S. Food and Drug Administration (FDA). These appointments, as well as recent statements from HHS and FDA leadership, align with the Trump administration’s intention to use AI to improve regulatory efficiency at HHS and beyond.

...

Read More

Eye on FDA

April 23, 2025

This week, the U.S. Food and Drug Administration (FDA), in collaboration with the Department of Health and Human Services (HHS), announced a series of new measures to phase out all petroleum-based synthetic dyes in food by the end of 2026. This initiative is part of the broader “Make America Healthy Again” (MAHA) agenda aimed at bolstering food safety. Citing growing concerns about the potential role of petroleum-based food dyes in childhood diabetes, obesity, depression and attention-deficit/hyperactivity disorder (ADHD), the agency plans to establish a national standard and timeline for the food industry to transition to natural alternatives.

...

Read More

Eye on FDA

April 16, 2025

On April 10, 2025, the Food and Drug Administration (FDA) announced its plan to replace animal testing in the development of monoclonal antibody therapies and other drugs in one of the first announcements by the agency since Commissioner Makary was confirmed to lead it. In its announcement, FDA highlighted that this more modern approach is designed to improve drug safety and accelerate the evaluation process, while also reducing animal experimentation, lowering research and development costs, and lowering drug prices.

...

Read More

Eye on FDA

April 2, 2025

On March 31, 2025, Judge Sean D. Jordan of the U.S. District Court for the Eastern District of Texas issued an opinion and judgment in American Clinical Laboratory Association v. FDA. Judge Jordan’s decision vacates and sets aside the Food & Drug Administration’s (FDA) final rule, Medical Devices; Laboratory Developed Tests (the LDT Rule).1 The LDT Rule would have required laboratories offering LDTs to meet medical device requirements. The preamble to the LDT Rule provided a multi-stage phase out of FDA’s enforcement discretion policy, under which the first set of regulatory requirements would have been actively enforced beginning May 6. While many labs are breathing a sigh of relief after the publication of this order, questions remain as to how the agency will proceed and the broader implications for regulation of lab tests and in vitro diagnostics generally.

...

Read More

Eye on FDA

March 24, 2025

In the past week, the U.S. Food and Drug Administration (FDA), in collaboration with the Department of Health and Human Services (HHS) announced three new initiatives related to food safety and food supply chain transparency. Outlined below, these new initiatives align with HHS Secretary Robert F. Kennedy Jr.’s recent announcements to focus on bolstering food safety, including the recent directive to the FDA to explore the revision of the longstanding Generally Recognized as Safe (GRAS) rule.

...

Read More

Eye on FDA

March 12, 2025

The Food and Drug Administration (FDA) has updated its website to provide new information on data integrity concerns relating to medical devices.

...

Read More

Eye on FDA

March 12, 2025

United States Department of Health and Human Services (HHS) Secretary Kennedy recently directed the U.S. Food and Drug Administration (FDA) to consider rulemaking to revise its longstanding regulations and guidance governing the oversight of food ingredients to eliminate the ability of individuals and companies to self-affirm that their ingredients are Generally Recognized as Safe (GRAS). This would mark a massive shift in how new food ingredients are introduced to the market.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.